Your browser doesn't support javascript.
loading
Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
Giuliani, Stefano; Paraboschi, Irene; McNair, Angus; Smith, Myles; Rankin, Kenneth S; Elson, Daniel S; Paleri, Vinidh; Leff, Daniel; Stasiuk, Graeme; Anderson, John.
Afiliación
  • Giuliani S; Wellcome/EPSRC Centre for Interventional and Surgical Sciences, University College London, London W1W 7TY, UK.
  • Paraboschi I; Cancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.
  • McNair A; Department of Specialist Neonatal and Paediatric Surgery, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK.
  • Smith M; Department of Biomedical and Clinical Science, University of Milano, 20157 Milan, Italy.
  • Rankin KS; National Institute for Health Research Bristol Biomedical Research Centre, Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK.
  • Elson DS; Department of Gastrointestinal Surgery, North Bristol NHS Trust, Bristol BS10 5NB, UK.
  • Paleri V; The Sarcoma, Melanoma and Rare Tumours Unit, The Royal Marsden Hospital, Institute Cancer of Research, London SW3 6JJ, UK.
  • Leff D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
  • Stasiuk G; North of England Bone and Soft Tissue Tumour Service, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.
  • Anderson J; Hamlyn Centre for Robotic Surgery, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK.
Cancers (Basel) ; 16(5)2024 Mar 04.
Article en En | MEDLINE | ID: mdl-38473402
ABSTRACT
This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative identification of the tumor margins of extra-hematological solid tumors. For each of them, the targeted antigen, the mAb generic/commercial name and format, and clinical indications are presented, together with utility, doses, and the timing of administration. Based on the current scientific evidence in humans, the top three mAbs that could be prepared in a GMP-compliant bank ready to be delivered for surgical purposes are proposed to speed up the translation to the operating room and produce a few readily available "off-the-shelf" injectable fluorescent probes for safer and more effective solid tumor resection.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article